Literature DB >> 27838285

The influence of mortality rate from membrane flux for end-stage renal disease: A meta-analysis.

Feng Zhao1, Zhipeng Wang2, Lin Liu3, Sheng Wang4.   

Abstract

To evaluate the influence of the high-flux hemodialysis (HFHD) and the low-flux hemodialysis (LFHD) on mortality rate for end-stage renal disease (ESRD). Four electronic databases including PubMed, EMBASE, the Cochrane Library, and ClinicalTrails were searched to identify relevant randomized clinical trials up to 31 August 2015. Seven studies enrolling a total of 4412 patients were included in this meta-analysis. For all-cause mortality comparing with LFHD, the result showed that there were significant difference (RR=0.75; 95% CI [0.60-0.94]; I2=84%; P<0.00001). For death due to infection comparing with LFHD, the result showed that there was no significant difference (RR=0.92; 95% CI [0.75-1.13]; I2=0%; P=0.86). For cardiovascular mortality, the overall meta-analysis result showed that there was a significant difference between the HFHD versus the LFHD (RR=0.75; 95% CI [0.60-0.94]; I2=55%; P=0.11). Publication bias was not detected by funnel plot. Based on these results, our study suggests that the HFHD has superior effectiveness over LFHD for long-term survival in ESRD.
Copyright © 2016 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  All-cause mortality; Cardiovascular mortality; End-stage renal; Hemodialysis; Meta-analysis

Mesh:

Year:  2016        PMID: 27838285     DOI: 10.1016/j.nephro.2016.07.445

Source DB:  PubMed          Journal:  Nephrol Ther        ISSN: 1769-7255            Impact factor:   0.722


  1 in total

1.  Effect of changing treatment to high-flux hemodialysis (HFHD) on mortality in patients with long-term low flux hemodialysis (LFHD): a propensity score matched cohort study.

Authors:  Shuxin Liu; Hong Liu; Zhihong Wang; Lanbo Teng; Cui Dong; Tingting Gui; Yu Zhang
Journal:  BMC Nephrol       Date:  2020-11-16       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.